Altis Labs
PrivateLast Round
Series A
Sep 17, 2026
Total Funding Raised
$31M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Altis Labs operates in Healthcare & Life Sciences and is based in Toronto. Its latest recorded funding round was a Series A round in September 2026.
Altis Labs is a computational imaging company that provides an AI-powered software platform, Nota, to help biopharmaceutical companies accelerate clinical trials.
Sector
Healthcare & Life Sciences
Verticals
Clinical Trials, Medical Imaging, Healthcare Analytics, Drug Discovery, Computer Vision
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Altis Labs Comparables
Compare Altis Labs with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Radiomics | 87% | |
| QMENTA | 86% | |
| Qureight | 85% |
For institutional investors. Book with your work email.
Altis Labs Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 17, 2026 | ||||
| Seed | Jun 21, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Altis Labs Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fusion Fund | Series A |
| Innovation Endeavors | Series A |
| OrbiMed | Series A |
| Lumira Ventures | Series A |
| Qiming | Series A |
| Benchstrength | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 17, 2026
$25M round led by OrbiMed and Qiming
- Aug 21, 2026
Monthly visitors grew 67% MoM, reaching 5.9K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 18, 2026
Altis Labs, Inc. is developing AI-based endpoints and outcome measures for clinical trials to accelerate evidence generation in cancer drug development.
- attends_eventSep 17, 2026
Altis Labs, Inc. attended event World Conference on Lung Cancer on Jul 1st '26.
- receives_financingSep 17, 2026
Altis Labs, Inc. closed a $25M Series A financing co-led by OrbiMed and Qiming Venture Partners USA in Canada on Sep 17th '26 to expand its AI models across additional cancer types, scale commercial deployment, and establish AI endpoints as a standard for oncology trials.
For institutional investors. Book with your work email.
Altis Labs Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Altis Labs's valuation, stock price, and market status.
Is Altis Labs a public or private company?
Altis Labs is a private company.
What is the current stock price of Altis Labs?
Altis Labs is a private company, so its shares have no public market price. Caplight tracks Altis Labs's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Altis Labs worth (valuation)?
Valuation information for Altis Labs is not publicly available.
Can I buy Altis Labs stock?
Altis Labs shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Altis Labs's last funding round?
Altis Labs's most recent funding round was Series A on September 17, 2026.
Who are the main investors in Altis Labs?
Key investors in Altis Labs include OrbiMed, Qiming, Benchstrength.
Will Altis Labs IPO soon?
No public IPO plans have been announced for Altis Labs.
How can I track Altis Labs secondary market activity?
Caplight tracks bids, offers, and trades in Altis Labs's shares on secondary markets.